Poseida Therapeutics' (PSTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q2 2024 earnings at ($0.43) EPS, Q3 2024 earnings at ($0.46) EPS, […]

Related Keywords

Ohio ,United States , ,Mirae Asset Global Investments Co ,Poseida Therapeutics Inc ,Silverarc Capital Management ,Nasdaq ,Barclays Plc ,Poseida Therapeutics ,Free Report ,Get Free Report ,Capital Management ,Employees Retirement System ,Asset Global Investments ,Heme Malignancies ,Poseida Therapeutics Daily ,